BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20700794)

  • 1. Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects.
    Mochizuki H; Itakura H; Yokoyama T; Takamatsu M; Kiuchi Y
    Jpn J Ophthalmol; 2010 Jul; 54(4):286-90. PubMed ID: 20700794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
    Ge J; Li X; Sun X; He X; Zhang H
    Zhonghua Yan Ke Za Zhi; 2015 Feb; 51(2):95-102. PubMed ID: 25907999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
    Konstas AG; Quaranta L; Katsanos A; Riva I; Tsai JC; Giannopoulos T; Voudouragkaki IC; Paschalinou E; Floriani I; Haidich AB
    Br J Ophthalmol; 2013 Dec; 97(12):1510-5. PubMed ID: 23681371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation.
    Ota T; Murata H; Sugimoto E; Aihara M; Araie M
    Invest Ophthalmol Vis Sci; 2005 Jun; 46(6):2006-11. PubMed ID: 15914616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
    Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
    Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Ocular Pulse Amplitude-Lowering Effects of Tafluprost and Latanoprost by Dynamic Contour Tonometry.
    Park SH; Yoo SH; Ha SJ
    J Ocul Pharmacol Ther; 2015 Dec; 31(10):617-22. PubMed ID: 26348718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.
    Konstas AG; Boboridis KG; Kapis P; Marinopoulos K; Voudouragkaki IC; Panayiotou D; Mikropoulos DG; Pagkalidou E; Haidich AB; Katsanos A; Quaranta L
    Adv Ther; 2017 Jan; 34(1):221-235. PubMed ID: 27913991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males.
    Sutton A; Gilvarry A; Ropo A
    J Ocul Pharmacol Ther; 2007 Aug; 23(4):359-65. PubMed ID: 17803434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects.
    Kawaguchi I; Higashide T; Ohkubo S; Kawaguchi C; Sugiyama K
    Jpn J Ophthalmol; 2012 Jul; 56(4):346-53. PubMed ID: 22669351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys.
    Kurashima H; Asai Y; Aihara M; Ishida N; Nakamura M; Araie M
    J Glaucoma; 2012 Feb; 21(2):123-8. PubMed ID: 21423041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
    Wong TT; Aung T; Ho CL
    Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure.
    Bacharach J; Dubiner HB; Levy B; Kopczynski CC; Novack GD;
    Ophthalmology; 2015 Feb; 122(2):302-7. PubMed ID: 25270273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peak pressures: crossover study of timolol and latanoprost.
    Sihota R; Saxena R; Agarwal HC; Pandey RM; Gulati V
    Eur J Ophthalmol; 2003 Jul; 13(6):546-52. PubMed ID: 12948313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
    Topouzis F; Melamed S; Danesh-Meyer H; Wells AP; Kozobolis V; Wieland H; Andrew R; Wells D
    Eur J Ophthalmol; 2007; 17(2):183-90. PubMed ID: 17415690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two- and three-times-daily topical ophthalmic application of 0.005% latanoprost solution in clinically normal dogs.
    Tofflemire KL; Whitley EM; Allbaugh RA; Ben-Shlomo G; Robinson CC; Overton TL; Thiessen CE; Evans EA; Griggs AN; Adelman SA; Ludwig AL; Jens JK; Ellinwood NM; Peterson CS; Whitley RD
    Am J Vet Res; 2015 Jul; 76(7):625-31. PubMed ID: 26111092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety.
    Kuwayama Y; Nomura A
    Adv Ther; 2014 Apr; 31(4):461-71. PubMed ID: 24615289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
    Maeda-Chubachi T; Chi-Burris K; Simons BD; Freedman SF; Khaw PT; Wirostko B; Yan E;
    Ophthalmology; 2011 Oct; 118(10):2014-21. PubMed ID: 21680022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure.
    Liu JH; Kripke DF; Weinreb RN
    Am J Ophthalmol; 2004 Sep; 138(3):389-95. PubMed ID: 15364220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
    Uusitalo H; Pillunat LE; Ropo A;
    Acta Ophthalmol; 2010 Feb; 88(1):12-9. PubMed ID: 20420586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring.
    Cho SY; Kim YY; Yoo C; Lee TE
    Jpn J Ophthalmol; 2016 Jan; 60(1):27-34. PubMed ID: 26411460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.